Inovio Pharmaceuticals (INO) Stock Analysis & AI Equity Report
Inovio Pharmaceuticals (INO) overview
Inovio Pharmaceuticals (INO) stock analysis and AI equity research. For financial year 2025, Valuatum's model shows revenue of USD 0.1m and operating profit of USD -86.8m; the year-end share price was 1.74 USD and market capitalisation was USD 120m. Inovio Pharmaceuticals is covered by Valuatum but does not yet have a published AI equity report. Generate a fresh report to get Inovio Pharmaceuticals's valuation, segment value analysis, reverse valuation, financial forecasts, key ratios, risks and catalysts.
Key metrics & valuation multiples
About Inovio Pharmaceuticals
Inovio Pharmaceuticals develops DNA medicine candidates for diseases associated with human papillomavirus, cancer, and infectious diseases. Its candidates are biologic medicines delivered using the company’s CELLECTRA electroporation devices, making them drug-device combination products. The company’s pipeline includes INO-3107, a candidate being evaluated as a potential treatment for adults with recurrent respiratory papillomatosis.
Generate the Inovio Pharmaceuticals report
Inovio Pharmaceuticals is on Valuatum's coverage list, but a full AI equity report hasn't been generated yet. Order one now for the complete company value map, reverse valuation, risk & catalyst analysis, and financial statements and estimates — plus a downloadable PDF.
Sources & methodology
Financial figures are sourced from Valuatum's financial model for Inovio Pharmaceuticals and represent financial year 2025. See the methodology for the full Valuatum AI equity research framework.
Disclaimer: This is an AI-generated research material for informational purposes only. It is not investment advice or a buy/sell recommendation. Always perform your own analysis. Valuatum Oy, Helsinki, Finland.
Analyst reports on Inovio Pharmaceuticals
Each report here is this company's Valuatum report re-run with an analyst's own assumptions and published under their name. They are ordered by a score out of five: what other analysts felt the work added over the engine's default report.